Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy

被引：63

作者：

Reddick, WE

Bhargava, R

Taylor, JS

Meyer, WH

Fletcher, BD

机构：

[1] Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, 38101

[2] Department of Electrical Engineering, University of Memphis, Memphis, Tennessee

[3] Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, 38101

[4] Departments of Radiology, University of Tennessee. School of Medicine. Memphis. TN

[5] Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, 38101

[6] Departments of Radiology, University of Tennessee. School of Medicine. Memphis. TN

[7] St. Jude Children's Research Hospital, Memphis, Tennessee, 38101

[8] University of Tennessee. School of Medicine, Memphis, Tennessee

[9] Departments of Diagnostic Imaging, School of Medicine. Memphis. TN

[10] Departments of Radiology, University of Tennessee. School of Medicine. Memphis. TN

来源：

JOURNAL OF MAGNETIC RESONANCE IMAGING | 1995年 / 5卷 / 06期

关键词：

bone neoplasms; MR; contrast enhancement; gadopentetate dimeglumine; image processing; osteosarcoma; perfusion studies;

D O I：

10.1002/jmri.1880050612

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Assessment of osteosarcoma response to neoadjuvant chemotherapy has prognostic implications, but conventional imaging techniques have been unable to provide an accurate quantitative measure of tumor response, We developed an analysis of dynamic contrast-enhanced MR imaging (DEMRI) to render an image of dynamic vector magnitudes (DVM) and to summarize the result in a quantitative parameter, mean DVM for the lesion (mu(DVM)). We compared the mu(DVM) from the examination before surgery with histologic results from an en bloc resection of the tumor in 19 cases. The final mu(DMV) value provided an accurate (89.5%) measure of tumor necrosis in osteosarcoma, Further, we analyzed the findings in 17 patients with osteosarcoma who completed three DEMRI examinations during the course of therapy. Tumors with higher mu(DVM) values at presentation had greater decreases in the parameter over the course of therapy, These results are consistent with the distribution of DVM values in these lesions serving as an indicator of tumor perfusion and a possible surrogate variable for drug delivery.

引用

页码：689 / 694

页数：6

共 23 条

[1]

Link MP, Goorin AM, Miser AW, Et al., The effect of adjuvant chemotherapy on relapse‐free survival in patients with osteosarcoma of the extremity, N Engl J Med, 314, pp. 1600-1606, (1986)

[2]

Glasser DB, Lane JM, Huvos AG, Marcome RC, Rosen G, Survival, prognosis, and therapeutic response in osteogenlc sarcoma, Cancer, 69, pp. 698-708, (1992)

[3]

Rosen G, Capparros B, Huvos AG, Et al., Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy, Cancer, 49, pp. 1221-1230, (1982)

[4]

Rosen G, Marcove RC, Caparros B, Nirenberg A, Kasloff C, Huvos AG, Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery, Cancer, 43, pp. 2163-2177, (1979)

[5]

Raymond AK, Chawla SP, Carrasco CH, Et al., Osteosarcoma chemotherapy effect:a prognostic factor, Semin Diagn Pathol, 4, pp. 212-236, (1987)

[6]

Meyers PA, Heller G, Healy J, Et al., Chemotherapy for non‐metastatic osteogenic osteosarcoma: the Memorial Sloan‐Kettering experience, J Clin Oncol, 10, pp. 5-15, (1992)

[7]

Winkler K, Beron G, Delling G, Et al., Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS‐82) with salvage chemotherapy based on histological tumor response, J Clin Oncol, 6, pp. 329-337, (1988)

[8]

Gherlinzoni F, Picci P, Bacci G, Campanacci D, Limb sparing versus amputation in osteosarcoma: correlation between local control, surgical margins, and tumor necrosis: Istituto Rizzoli experience, Annals of Oncology, 3, pp. 23-27, (1992)

[9]

Huvos AG, Rosen G, Marcove RC, Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement, Arch Pathol Lab Med, 101, pp. 14-18, (1977)

[10]

Picci P, Bacci G, Campanacci M, Et al., Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor, Cancer, 56, pp. 1515-1521, (1985)

← 1 2 3 →